What are the safety and efficacy of ACE inhibitors and ARBs after CABG in previously na ve low- to moderate-risk patients?
The safety and efficacy of ACE inhibitors and ARBs after CABG in previously na ve low- to moderate-risk patients (ie, subjects without diabetes mellitus or renal insufficiency and with or Hillis et al 2011 ACCF/AHA CABG Guideline e681 without asymptomatic moderate LV systolic dysfunction) are uncertain; however, ACE inhibitors and ARBs must be used with caution in these subjects. They should not be instituted in the immediate postoperative period if the systolic arterial pres- sure is 100 mm Hg or if the patient develops hypotension in the hospital after receiving them.